Taro pharmaceutical industries ltd (TARO)
Income statement / Yearly
Mar'18Mar'17Mar'16Mar'15Mar'14Mar'13Dec'11Dec'10Dec'09
Sales, net

661,913

879,387

950,751

862,944

759,285

670,954

505,668

392,535

355,936

Cost of sales

198,405

207,860

169,743

186,359

179,279

176,128

176,143

159,158

146,920

Impairment

0

276

2,042

-

-

-

-

-

3,363

Impairment

-

-

-

-

-

-

-

-

171

Gross profit

463,508

671,251

778,966

676,585

580,006

494,826

329,525

233,377

208,845

Operating expenses:
Research and development

70,418

70,644

71,160

65,510

55,430

46,508

30,867

36,393

33,303

Selling, marketing, general and administrative

88,196

85,656

92,365

87,644

91,733

86,438

93,918

107,902

100,344

Settlements and loss contingencies

-1,884

-

-973

4,200

-2,590

-33,300

0

-

-

Total operating expenses

160,498

156,300

164,498

148,954

149,753

166,246

124,785

144,295

137,010

Operating income

303,010

514,951

614,468

527,631

430,253

328,580

204,740

89,082

71,835

Financial expenses (income), net

-12,531

34,636

19,672

51,311

12,285

3,931

3,697

-11,840

-13,575

Other gain, net

1,889

11,211

2,680

2,738

1,369

3,352

609

755

548

Income before income taxes

292,368

560,798

636,820

581,680

443,907

335,863

209,046

77,997

58,808

Tax expense

81,954

103,780

95,313

96,059

82,729

67,799

24,551

10,477

-69,657

Income from continuing operations

210,414

457,018

541,507

485,621

361,178

268,064

184,495

67,520

128,465

Net loss from discontinued operations attributable to Taro

-335

-352

-236

-787

-319

-1,194

-1,217

-2,969

-11,714

Net income

210,079

456,666

541,271

484,834

360,859

266,870

183,278

64,551

116,751

Net (loss) income attributable to non-controlling interest

-1,071

310

339

577

472

664

598

473

2,728

Net income attributable to Taro

211,150

456,356

540,932

484,257

360,387

266,206

182,680

64,078

114,023

Net income from continuing operations attributable to Taro

211,485

456,708

541,168

485,044

360,706

267,400

183,897

67,047

125,737

Net loss from discontinued operations attributable to Taro

-335

-352

-236

-787

-319

-1,194

-1,217

-2,969

-11,714

Net income attributable to Taro

211,150

456,356

540,932

484,257

360,387

266,206

182,680

64,078

114,023

Net income per ordinary share from continuing operations attributable to Taro:
Basic and Diluted

5.27

11.06

12.63

-

-

-

-

-

-

Basic

-

-

-

11.32

8.15

5.99

4.14

1.66

3.21

Diluted

-

-

-

11.32

8.15

5.98

4.14

1.60

3.10

Net loss per ordinary share from discontinued operations attributable to Taro:
Basic and Diluted

-0.01

-0.01

-0.01

-

-

-

-

-

-

Basic

-

-

-

-0.01

-0.01

-0.03

-0.03

-0.07

-0.30

Diluted

-

-

-

-0.01

-0.01

-0.03

-0.03

-0.07

-0.29

Net income per ordinary share attributable to Taro:
Basic and Diluted

5.26

11.05

12.62

-

-

-

-

-

-

Basic

-

-

-

11.31

8.14

5.96

4.11

1.59

2.91

Diluted

-

-

-

11.31

8.14

5.95

4.11

1.53

2.81

Weighted-average number of ordinary shares used to compute net income per share:
Basic and Diluted

40,155

41,301

42,832

-

-

-

-

-

-

Basic

-

-

-

42,833

44,276

44,677

44,406

40

39,232

Diluted

-

-

-

42,833

44,279

44,715

44,491

41

40,568